A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : VEGFRs / vascular endothelial growth factor receptors

[Related PubMed/MEDLINE]
Total Number of Papers: 91
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   VEGFRs  (>> Co-occurring Abbreviation)
Long Form:   vascular endothelial growth factor receptors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model. ATM, GBM, ROS
2020 Microvessel density and vascular endothelial growth factor receptors in breast carcinoma under the influence of rapamycin and platelet factor 4. MNU
2020 Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression. ECs
2020 PET Imaging of VEGFR with a Novel 64Cu-Labeled Peptide. PET
2019 A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. CTLs, NF2
2019 Multiplexing Angiogenic Receptor Quantification via Quantum Dots. HUVECs, NRP-1, RTKs
2019 Sunitinib in the Treatment of Thyroid Cancer. ATC, DeTC, DTC, FLT3, GIST, MTC, PDGFRs, TKI
2019 Vascular Endothelial Growth Factor Receptor 3 Regulates Endothelial Function Through beta-Arrestin 1. ARRB, PAH
2018 Apatinib as targeted therapy for sarcoma. VEGF
10  2018 Computational Design of Antiangiogenic Peptibody by Fusing Human IgG1 Fc Fragment and HRH Peptide: Structural Modeling, Energetic Analysis, and Dynamics Simulation of Its Binding Potency to VEGF Receptor. ---
11  2018 Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors. ---
12  2018 Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model. ---
13  2018 Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. FGFRs, uHCC
14  2018 Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. PDGFR, PFS, TKI
15  2017 Arylurea Derivatives: A Class of Potential Cancer Targeting Agents. CDKs, Chks, EGFRs, FGFRs, FLT3, HDAC, IGF-1R, LIMK, MMPs, PDGFRs, SARs, Smo, SUMO E1
16  2017 Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. RCC, TKIs
17  2017 Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2. ---
18  2017 Hsp90beta promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma. ---
19  2017 Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy. TKIs
20  2017 Tivozanib: a new treatment option for renal cell carcinoma. EMA, mTOR, RCC
21  2016 Negative pressure wound therapy induces early wound healing by increased and accelerated expression of vascular endothelial growth factor receptors. NPWT
22  2016 Practical first-line management of renal cell carcinoma in a community practice. HRQoL, mRCC, TKI
23  2016 Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. MCTs, PDGFRs, RTK
24  2016 Sunitinib in the treatment of metastatic renal cell carcinoma. IFN-alpha, mRCC, TKI
25  2016 Suppression of Allograft Rejection with Soluble VEGF Receptor 2 Chimeric Protein in a Mouse Model of Corneal Transplantation. ---
26  2016 The Management of Medullary Thyroid Carcinoma in the Era of Targeted Therapy. MEN, MTC, RET
27  2015 Aortic dissection during antiangiogenic therapy with sunitinib. A case report. mTOR
28  2015 Chronic and non-healing wounds: The story of vascular endothelial growth factor. sVEGFR-1, VEGF
29  2015 Clinical utility of ramucirumab in advanced gastric cancer. VEGF
30  2015 PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction. LV, MI, PDGFRs, PET
31  2015 Synthesis, Characterization, and Biological Evaluation of a Dual-Action Ligand Targeting alphavbeta3 Integrin and VEGF Receptors. HUVECs
32  2014 Combined therapeutic efficacy of 188Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells. 188Re
33  2014 Inverse correlation of phospho-KDR/Flk-1 expression and stage of colorectal cancer: implication of the significance of neoangiogenesis in activated VEGFR-2 expressing early stage colorectal adenocarcinomas. ---
34  2014 Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm. EGFR, MTC
35  2014 Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERalpha and VEGFR-2. ERalpha
36  2014 The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. CD, FGFR1, IHC, UC
37  2013 A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. MBC, PK, TKI
38  2013 Cediranib for metastatic alveolar soft part sarcoma. ASPS, ORR
39  2013 Expression of VEGF-receptors in TMJ synovium of rabbits with experimentally induced internal derangement. MRI, PCR, TMJ
40  2013 Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. CDCA1, CT, KIF20A, OS, PFS
41  2013 In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. HAEC, PET
42  2013 Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs. FGFRs, LVL, MVD
43  2013 Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. MTD, NSCLC
44  2013 Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. CR, DLBCL
45  2013 Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion. ADC, alpha-SMA, EC, MPE, MVD, PC, PDGFRs
46  2013 Targeting the fibroblast growth factor receptors for the treatment of cancer. EGFRs, FGFR, PDGFRs, RTKs
47  2013 Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. CSF-1, PDGFR, TKIs, TKRs
48  2013 Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone. TGF
49  2013 VEGFR and type-V RTK activation and signaling. CSFR, KI, PDGFR, PLC-gamma-PKC, RTK, TK, TM
50  2012 Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. EGFR, FGFR2
51  2012 Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. TSH
52  2012 Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. MBC, OS, TTP
53  2012 Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD. ---
54  2012 Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-gamma-related pathways. ERK, PKC, PLC, TH
55  2012 Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. ---
56  2012 VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. ---
57  2011 Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. AT1, IUGR, PlGF
58  2011 Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. ABC, FGFRs, MDR, PDGFRs
59  2011 Heart failure associated with sunitinib: lessons learned from animal models. AMPK, PDGFRs
60  2011 Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. HCC, OS, PDGFRs, RECIST, sKIT, sVEGFR-2, sVEGFR-3, TTP, VEGF
61  2011 Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. LECs, VEGFR-3
62  2011 Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. DTX, nNLC, tNLC
63  2011 Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here? EGF, HER-2, PDGF
64  2011 Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. ALP, VEGF
65  2011 Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. CI, GIST, PDGFRs, PR
66  2010 Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. LNM, NSCLC, PDGFRs, PDGFs
67  2010 Neuropilin 2 deficiency does not affect cortical neuronal viability in response to oxygen-glucose-deprivation and transient middle cerebral artery occlusion. NRP2, OGD
68  2010 Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer. pVEGFR-2
69  2010 Targeted molecular imaging of VEGF receptors overexpressed in ischemic microvasculature using chitosan-DC101 conjugates. ---
70  2009 Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. PDGFRs, SUTENT
71  2009 Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4. PDGFRs, RTK, RTKs
72  2009 Vascular endothelial growth factor receptor-1 (VEGFR-1) expression in human corneal fibroblast decreased with age. RT-PCR, VEGFR1, VEGFR1
73  2008 Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. HDACs, HDIs, HSP
74  2008 Developments in targeted therapy of advanced gastrointestinal stromal tumors. CSF-1R, FLT3, GISTs, PDGFRA
75  2008 Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. ---
76  2008 Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Gal-1, MAP, NRP-1
77  2008 Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. GIST, PR, SD
78  2008 Soluble Flt-1 regulates Flk-1 activation to control hematopoietic and endothelial development in an oxygen-responsive manner. VEGF
79  2007 Expression and function of vascular endothelial growth factor receptors (Flt-1 and Flk-1) in vascular adventitial fibroblasts. sFlt-1, VEGF
80  2007 Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. EL-MSC, MSCs, SSc
81  2006 Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. IF, NRPs, VEGF
82  2006 Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. CRC, SFKs, VEGF
83  2006 VEGF receptor signalling - in control of vascular function. ---
84  2005 Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. PDGFRs
85  2004 Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. MAPK
86  2004 Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. HPDE, HUVECs, NRPs, VEGF
87  2003 Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. PLC-gamma1
88  2003 SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. ---
89  2003 VEGF receptor expression and signaling in human bladder tumors. GAP, GEFs, SPK1, SPP
90  2002 Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. ---
91  2002 Caenorhabditis elegans receptors related to mammalian vascular endothelial growth factor receptors are expressed in neural cells. ---